12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Androgen Receptor ( AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS).

          Aim

          To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor ( AR) gene are implicated in PFS.

          Methods

          AR polymorphisms were studied according to PFS symptoms in 66 white participants (31.8% Italian, 28.8% American, and 39.4% other).

          Main Outcome Measures

          Symptoms were investigated by an ad hoc 100-item questionnaire and the Arizona Sexual Experience Scale and Aging Male Symptom Scale (AMS). (CAG)n and (GGN)n repeats were categorized as short ([CAG]9–19, [GGN]<23), medium ([CAG]20–24, [GGN]23), or long ([CAG]25–37, [GGN]>23).

          Results

          Median age was 32 years, duration of finasteride use was 360 days, and time from finasteride discontinuation was 1,053 days. We observed several frequency differences in symptoms according to (CAG)n and (GGN)n repeat numbers. Three AMS items were worse for medium (GGN)23 than for long (GGN)>23 carriers and one item was worse for short (GGN)<23 carriers. The AMS item for decrease in sexual desire or libido was worse for short (CAG)9–19 carriers than for medium (CAG)20–24 carriers. Through the ad hoc questionnaire, significant findings in (CAG)n and/or (GGN)n repeats were obtained for penile discomfort, loss of scrotal sensitivity, scrotal discomfort, less pubic hair, loss of perceived perineal fullness, increased sperm density, involuntary muscle spasms, loss of muscle tone, increased weight (>2 kg), increased skin dryness, and onset of symptoms after finasteride use.

          Conclusion

          This study showed that short and/or long (CAG)n and (GGN)n repeats had different frequencies according to symptoms reported by patients with PFS, likely reflecting the vast array of genes modulated by the AR. This study showed a U-curvilinear profile of (CAG)n repeats for skin dryness symptoms, where the two extremes exhibited a worse condition than medium repeats. Further studies are necessary to investigate the PFS pathophysiology using a precision medicine approach.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          The Arizona Sexual Experience Scale (ASEX): reliability and validity.

          Although sexual dysfunction is common in psychiatric patients, quantification of sexual dysfunction is limited by the paucity of validated, user-friendly scales. In order to address this problem, the authors have developed the Arizona Sexual Experiences Scale (ASEX), a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. This study assesses the internal consistency, test-retest reliability, and convergent and discriminant validity of the ASEX.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study.

            The role of testosterone (T) in regulating body composition is conflicting. Thus, our goal is to meta-analyse the effects of T supplementation (TS) on body composition and metabolic outcomes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Persistent sexual side effects of finasteride for male pattern hair loss.

              Finasteride has been associated with reversible adverse sexual side effects in multiple randomized, controlled trials for the treatment of male pattern hair loss (MPHL). The Medicines and Healthcare Products Regulatory Agency of the United Kingdom and the Swedish Medical Products Agency have both updated their patient information leaflets to include a statement that "persistence of erectile dysfunction after discontinuation of treatment with Propecia has been reported in post-marketing use." We sought to characterize the types and duration of persistent sexual side effects in otherwise healthy men who took finasteride for MPHL. We conducted standardized interviews with 71 otherwise healthy men aged 21-46 years who reported the new onset of sexual side effects associated with the temporal use of finasteride, in which the symptoms persisted for at least 3 months despite the discontinuation of finasteride. The types and duration of sexual dysfunction and the changes in perceived sexual frequency and sexual dysfunction score between pre- and post-finasteride use. Subjects reported new-onset persistent sexual dysfunction associated with the use of finasteride: 94% developed low libido, 92% developed erectile dysfunction, 92% developed decreased arousal, and 69% developed problems with orgasm. The mean number of sexual episodes per month dropped and the total sexual dysfunction score increased for before and after finasteride use according to the Arizona Sexual Experience Scale (P<0.0001 for both). The mean duration of finasteride use was 28 months and the mean duration of persistent sexual side effects was 40 months from the time of finasteride cessation to the interview date. Study limitations include a post hoc approach, selection bias, recall bias for before finasteride data, and no serum hormone levels. Physicians treating MPHL should discuss the potential risk of persistent sexual side effects associated with finasteride. © 2011 International Society for Sexual Medicine.
                Bookmark

                Author and article information

                Contributors
                Journal
                Sex Med
                Sex Med
                Sexual Medicine
                Elsevier
                2050-1161
                23 December 2016
                March 2017
                23 December 2016
                : 5
                : 1
                : e61-e71
                Affiliations
                [1 ]Department of Medical and Biological Sciences, School of Medicine, University of Udine, Udine, Italy
                [2 ]Urological Hospital Department, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
                [3 ]Experimental and Clinical Pharmacology Unit, CRO Aviano National Cancer Institute, Italy
                [4 ]Hospital Department of Gynecology and Obstetrics, University Hospital Santa Maria della Misericordia, Udine, Italy
                [5 ]Department of Experimental and Clinical Medicine, University of Udine, Dermatology Clinic, University Hospital Santa Maria della Misericordia, Udine, Italy
                Author notes
                [] Corresponding Author: Sabina Cauci, PhD, Associate Professor, Dipartimento di Scienze Mediche e Biologiche, Università di Udine, Piazzale Kolbe 4, Udine 33100, Italy. Tel: +39-0432-494312; Fax: +39-0432-494301Dipartimento di Scienze Mediche e BiologicheUniversità di UdinePiazzale Kolbe 4Udine33100Italy sabina.cauci@ 123456uniud.it
                Article
                S2050-1161(16)30075-7
                10.1016/j.esxm.2016.11.001
                5302381
                28024997
                ae351c6e-3576-442c-8173-cbb4929c1465
                © 2016 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 1 September 2016
                : 10 November 2016
                Categories
                Original Research
                Basic Science

                5α-reductase inhibitor,post-finasteride syndrome,male pattern hair loss,androgenic alopecia,androgen receptor,cag polymorphism,ggn polymorphism,erectile dysfunction,sexual dysfunction,loss of libido,finasteride side effects,finasteride safety

                Comments

                Comment on this article